HK128095A - Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods - Google Patents

Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods

Info

Publication number
HK128095A
HK128095A HK128095A HK128095A HK128095A HK 128095 A HK128095 A HK 128095A HK 128095 A HK128095 A HK 128095A HK 128095 A HK128095 A HK 128095A HK 128095 A HK128095 A HK 128095A
Authority
HK
Hong Kong
Prior art keywords
plasmid
host
growth hormone
production
bgh
Prior art date
Application number
HK128095A
Other languages
English (en)
French (fr)
Inventor
Haim Aviv
Marian Gorecki
Amos Oppenheim
Tikva Vogel
Original Assignee
Bio-Technology General Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Technology General Corporation filed Critical Bio-Technology General Corporation
Publication of HK128095A publication Critical patent/HK128095A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)

Claims (30)

  1. Verfahren zur Herstellung eines tierischen Wachstumshormons oder eines Polypeptidanalogons davon mit im wesentlichen derselben Aminosäuresequenz und derselben biologischen Aktivität des korrespondierenden natürlich vorkommenden Hormons, umfassend das Vermehren einer geeigneten Escherichia coli-Wirtzelle, die den thermolabilen Repressor CI und ein Plasmid enthält, das unter geeigneten Bedingungen zur Expression des Hormons oder des Peptidanalogons davon in der Wirtzelle fähig ist, die die Bildung des Hormons oder des Polypeptidanalogons davon erlauben und das Gewinnen des resultierenden Hormons oder des Polypeptidanalogons davon, wobei das Plasmid ein doppelsträngiges DNA-Molekül umfaßt, das in 5' nach 3' Richtung,
    - den Promotor und Operator PLOL eines λ-Bakteriophagen;
    - eine N-Erkennungsstelle zum Binden von durch die Wirtzelle gebildetem Antiterminator-N-Protein;
    - eine Mutante CII ribosomale Bindungsstelle der Sequenz:
    - ein ATG-Initiationscodon;
    - eine DNS-Sequenz, die das in Phase mit dem ATG-Initiationscodon zu exprimierende Hormon oder Polypeptidanalogon codiert,
    aufweist und das darüberhinaus eine DNS-Sequenz umfaßt, die einen Replikationsursprung aus dem bakteriellen Plasmid pBR322 enthält, und die zur autonomen Replikation in der Escherichia coli-Wirtzelle fähig ist und ein Gen umfaßt, das mit einer selektierbaren oder identifizierbaren phänotypischen Eigenschaft einhergeht, die dann auftritt, wenn das Plasmid in der Escherichia coli-Wirtzelle vorhanden ist.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß es sich bei der Escherichia coli-Wirtzelle um den Stamm A1637 handelt.
  3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Plasmid ringförmig ist.
  4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Temperatur oberhalb 42°C liegt.
  5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Phänotypergebnis aus einer Arzneimittelresistenz oder Temperaturempfindlichkeit besteht.
  6. Verfahren nach Anspruch 5, dadurch gekennzeichnet, daß die Arzneimittelresistenz aus einer Ampicillin-, Chloramphenicol- oder Tetracyclinresistenz besteht.
  7. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die DNS mit Codierung für das Hormon oder Polypeptidanaloge Rinderwachstumshormon codiert.
  8. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die DNS mit Codierung für das Hormon oder Polypeptidanaloge Schweinewachstumshormon codiert.
  9. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die DNS mit Codierung für das Hormon oder Polypeptidanaloge Hühnerwachstumshormon codiert.
  10. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die DNS mit Codierung für das Hormon oder Polypeptidanaloge menschliches Wachstumshormon codiert.
  11. Verfahren nach Ansprüchen 1 und 7, dadurch gekennzeichnet, daß man ein mit pRec 2/3 bezeichnetes, die in Figur 2 dargestellte Restriktionskarte aufweisendes und unter der ATCC-Hinterlegungsnummer 39385 hinterlegtes Plasmid verwendet.
  12. Verfahren nach Ansprüchen 1 und 7, dadurch gekennzeichnet, daß man ein als pROll bezeichnetes, die in Figur 3 dargestellte Restriktionskarte aufweisendes und unter der ATCC-Hinterlegungsnummer 39390 hinterlegtes Plasmid verwendet.
  13. Verfahren nach Ansprüchen 1 und 10, dadurch gekennzeichnet, daß man ein mit pTV18(1) bezeichnetes, die in Figur 4 dargestellte Restriktionskarte aufweisendes und unter der ATCC-Hinterlegungsnummer 39386 hinterlegtes Plasmid verwendet.
  14. Verfahren nach Ansprüchen 1 und 10, dadurch gekennzeichnet, daß man ein als pTV104(2) bezeichnetes, die in Figur 4 dargestellte Restriktionskarte aufweisendes und unter der ATCC-Hinterlegungsnummer 39384 hinterlegtes Plasmid verwendet.
  15. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man das Wirtplasmidsystem eine geeignete Zeit lang bei 42°C wachsen und danach bei 37 - 39°C weiterwachsen läßt, wobei das Wachstum in einem geeigneten Medium erfolgt.
  16. Verfahren nach Anspruch 15, dadurch gekennzeichnet, daß man (das Wirtplasmidsystem) 10 - 30 min lang bei 42°C und danach so lange bei 37 - 39°C wachsen läßt, daß die gesamte Wachstumsdauer 60 - 90 min beträgt.
  17. Verfahren nach Anspruch 16, dadurch gekennzeichnet, daß man (das Wirtplasmidsystem) etwa 15 min bei 42°C und danach etwa 75 min bei 38 - 39°C wachsen läßt.
  18. Verfahren nach Anspruch 15, dadurch gekennzeichnet, daß man als geeignetes Medium ein mit Glucose oder Gehirn/Herz-Aufguß(infusion) versetztes Lactalbuminhydrolysat verwendet.
HK128095A 1983-07-15 1995-08-10 Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods HK128095A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51418883A 1983-07-15 1983-07-15

Publications (1)

Publication Number Publication Date
HK128095A true HK128095A (en) 1995-08-18

Family

ID=24046152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK128095A HK128095A (en) 1983-07-15 1995-08-10 Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods

Country Status (22)

Country Link
US (3) US4871835A (de)
EP (3) EP0131843B1 (de)
JP (3) JPH0687780B2 (de)
AT (2) ATE136934T1 (de)
AU (2) AU577298B2 (de)
BG (2) BG49718A3 (de)
BR (1) BR8403523A (de)
CA (1) CA1254527A (de)
CZ (1) CZ282867B6 (de)
DD (2) DD240217A5 (de)
DE (2) DE3486425T2 (de)
DK (1) DK347184A (de)
ES (2) ES534321A0 (de)
FI (1) FI90564C (de)
HK (1) HK128095A (de)
HU (1) HU209878B (de)
IE (2) IE64174B1 (de)
IL (8) IL72396A (de)
NZ (2) NZ208897A (de)
RO (1) RO91332B (de)
SK (1) SK278576B6 (de)
ZA (1) ZA845345B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340926A (en) * 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
US5236828A (en) * 1983-07-06 1993-08-17 Papas Takis S Plasmid pJL6
BG49718A3 (bg) * 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US5670371A (en) * 1983-07-15 1997-09-23 Bio-Technology General Corp. Bacterial expression of superoxide dismutase
US5332805A (en) * 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
EP0159123B1 (de) * 1984-03-06 1992-01-15 Eli Lilly And Company Expressionsvektoren für Rinderwachstumshormonderivate
CA1340597C (en) * 1984-08-27 1999-06-22 Haim Aviv Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
US5112744A (en) * 1984-08-27 1992-05-12 Bio-Technology General Corp. Plasmids for the production of human Cu-Zn superoxide dismutase, bacterial hosts containing the plasmids and methods for production and recovery of such superoxide dismutase
CA1267615A (en) * 1984-08-27 1990-04-10 Dan Hadary Method for recovering purified growth hormones from genetically engineered microorganisms
US5143836A (en) * 1984-08-27 1992-09-01 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda pl promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US6030611A (en) * 1984-08-27 2000-02-29 Bio-Technology General Corp. Therapeutic SOD compositions and uses thereof
US5759816A (en) * 1984-08-27 1998-06-02 Bio-Technology General Corp. Expression vectors containing λPL promoter and T1 T2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US4743546A (en) * 1985-02-13 1988-05-10 Biotechnica International, Inc. Controlled gene excision
US4861868A (en) 1985-02-22 1989-08-29 Monsanto Company Production of proteins in procaryotes
FR2579223B1 (fr) * 1985-03-25 1988-12-09 Genetica Procede de preparation microbiologique de la serum-albumine humaine
ATE76435T1 (de) 1985-06-26 1992-06-15 Upjohn Co Solubilisation und oxidation von somatotropin aus transformierten mikroorganismen.
US4788144A (en) * 1985-06-28 1988-11-29 International Minerals & Chemical Corp. Fermentation process for the high level production of swine growth
US4762784A (en) * 1985-07-15 1988-08-09 International Minerals & Chemical Corp. Fermemtation process for the high level production of bovine growth hormone
US4874703A (en) * 1985-08-26 1989-10-17 Eli Lilly And Company Expression vectors for use in E. coli
WO1987001708A2 (en) * 1985-09-18 1987-03-26 The Upjohn Company Enhanced bioactivity of mammalian somatotropin through selective deamidation
US5631227A (en) * 1985-09-18 1997-05-20 The Upjohn Company Somatotropin analogs
JPH07110232B2 (ja) * 1985-10-14 1995-11-29 株式会社日立製作所 遺伝子組換え大腸菌の遺伝子生産物を採取する方法および装置
US6610520B1 (en) 1985-11-22 2003-08-26 Bio-Technology General Corp. Gene encoding human manganese superoxide dismutase and recombinant polypeptide encoded thereby
IE59498B1 (en) * 1985-11-22 1994-03-09 Bio Technology General Corp Human manganese superoxide dismutase analog, plasmid for its expression and method of recovering it in enzymatically active form
ES2019874B3 (es) * 1986-10-08 1991-07-16 Upjohn Co Bioactividad mejorada de somatotropina de mamiferos mediante desamidacion selectiva.
US5089406A (en) * 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
GB8701848D0 (en) * 1987-01-28 1987-03-04 Celltech Ltd Polypeptides
WO1988006186A2 (en) * 1987-02-19 1988-08-25 The Upjohn Company cDNAs ENCODING SOMATOTROPIN, EXPRESSION VECTORS AND HOSTS
US5240837A (en) * 1987-02-19 1993-08-31 The Upjohn Company CDNAS encoding somatotropin, expression vectors and hosts
US5104796A (en) * 1987-04-06 1992-04-14 International Minerals & Chemical Corp. High titer production of human somatomedin c
US5047504A (en) * 1987-04-28 1991-09-10 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
US4966841A (en) * 1987-05-22 1990-10-30 The Board Of Regents Of The University Of Washington Enhanced vector production and expression of recombinant DNA products
US5030563A (en) * 1987-07-07 1991-07-09 Genetics Institute, Inc. Bacterial hypersecretion using mutant repressor sequence
US5079345A (en) * 1988-08-19 1992-01-07 Eli Lilly And Company Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
DE68919647T2 (de) * 1988-10-26 1995-05-11 American Cyanamid Co Verfahren zur Verringerung des Aggregatinhaltes in Wachstumshormonen gleichenden Stoffen.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0397834B1 (de) * 1988-10-28 2000-02-02 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
EP0441889A1 (de) * 1988-11-07 1991-08-21 Commission des Communautés Européennes Modifiziertes menschliches wachstumshormon
US4975529A (en) * 1989-08-18 1990-12-04 Monsanto Company Method of folding somatotropins
US6583115B1 (en) 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
IE912345A1 (en) * 1990-08-03 1992-02-12 Pharmacia Ab Treatment of human lactation failure
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
US5395761A (en) * 1991-11-27 1995-03-07 Eli Lilly And Company Plasmid pHKY334, an expression vector for EK-BGH and host cells transformed therewith
ZA94169B (en) * 1993-01-26 1994-09-07 Lilly Co Eli Non-denaturing potency assay for bovine somatotropin
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
US20020142965A1 (en) * 1994-11-15 2002-10-03 Metabolic Pharmaceuticals, Ltd. Treatment of obesity
US6335319B1 (en) 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
AU5881996A (en) * 1995-06-07 1996-12-30 Ohio University/Edison Biotechnology Institute Methods of treatment using growth hormone antagonists
KR970006498A (ko) * 1995-07-31 1997-02-21 유충식 활성형 인성장호르몬의 정제 방법
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
ATE216723T1 (de) 1996-02-13 2002-05-15 Japan Chem Res Hormones de croissance humaines mutantes et leur utilisation
BR9811755A (pt) * 1997-09-08 2000-08-29 Metabolic Pharmaceutical Ltd Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
DE19951765A1 (de) * 1999-10-27 2001-05-03 Thomas Schweder Wirts-Vektor-Systeme zur Überproduktion von thermolabilen Enzymen psychrophiler Organismen
KR100400638B1 (ko) * 2000-12-06 2003-10-08 주식회사 엘지생명과학 재조합 인간 성장호르몬 유사체의 분리방법
DK1368483T3 (da) 2001-03-09 2012-11-05 Genentech Inc Fremgangsmåde til fremstilling af polypeptider
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2446898A1 (de) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68404B (de) * 1979-06-01 1981-12-29 Univ California
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4426323A (en) * 1980-01-10 1984-01-17 Ionics, Incorporated Selected recovery of proteins from fermentation broths
US4443539A (en) * 1980-02-05 1984-04-17 The Upjohn Company Process for preparing bovine growth hormone
IL59690A (en) * 1980-03-24 1983-11-30 Yeda Res & Dev Production of bovine growth hormone by microorganisms and modified microorganisms adapted to produce it
EP0041767B1 (de) * 1980-06-06 1993-03-03 Biogen, Inc. Verbesserte Vektoren, Verfahren zur Herstellung solcher Vektoren und zur Expression von klonierten Genen
US4352443A (en) * 1980-06-24 1982-10-05 U.S. Cap & Closure, Inc. Dispenser having a trigger-bulb pump
JPS6045848B2 (ja) * 1980-07-31 1985-10-12 株式会社林原生物化学研究所 ヒト成長ホルモンの製造方法
IE52755B1 (en) * 1980-08-26 1988-02-17 Univ California Bovine pre-growth and growth hormone
DE3231658A1 (de) 1981-01-21 1983-11-17
EP0061250A3 (de) * 1981-03-23 1983-09-28 Biogen N.V. Verfahren zur Rückgewinnung von Produkten erzeugt durch Wirtorganismen
NZ201918A (en) * 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
US4665160A (en) * 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
IE55163B1 (en) * 1982-06-07 1990-06-20 Celltech Ltd A process for the preparation of chymosin
EP0103395A3 (de) * 1982-08-17 1985-05-22 Biogen N.V. DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von rinderwachstumshormonähnlichen Polypeptiden, mit grosser Ausbeute
EP0111814A3 (de) * 1982-12-16 1985-08-14 Mgi Pharma, Inc. Klonierung und Expression von nucleotiden Sequenzen die für Rinderwachstumshormon kodieren
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
WO1984002534A1 (en) * 1982-12-23 1984-07-05 Us Commerce Human growth hormone produced by recombinant dna in mouse cells
US4728609A (en) * 1983-01-10 1988-03-01 Hoffmann-La-Roche Inc. Recombinant growth hormone releasing factor
JPS59145876A (ja) * 1983-02-09 1984-08-21 株式会社リコー 開閉体用のヒンジ
AU574064B2 (en) * 1983-03-07 1988-06-30 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogues
EP0122080B1 (de) * 1983-03-25 1989-09-13 Celltech Limited Verfahren zur Herstellung eines Proteins
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
BG49718A3 (bg) * 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
AU587176B2 (en) * 1984-02-14 1989-08-10 Mycogen Plant Science, Inc. Transfer vector
US4767709A (en) * 1984-06-28 1988-08-30 The Johns Hopkins University Growth-related hormones
DE3426532A1 (de) * 1984-07-18 1986-01-30 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verwendung einer dna-sequenz zur expression sowie dna-struktur und expressionsvektor mit der dna-sequenz
CA1340597C (en) * 1984-08-27 1999-06-22 Haim Aviv Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
US4612367A (en) * 1985-04-08 1986-09-16 Eli Lilly And Company Process for purifying growth hormone-like materials
US4677196A (en) * 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4656255A (en) * 1985-09-09 1987-04-07 International Minerals & Chemical Corp. Protein recovery

Also Published As

Publication number Publication date
DE3485003D1 (de) 1991-10-10
SK524684A3 (en) 1997-10-08
BG49721A3 (bg) 1992-01-15
DD240217A5 (de) 1986-10-22
ES8602947A1 (es) 1985-12-01
BG49718A3 (bg) 1992-01-15
EP0131843A1 (de) 1985-01-23
ATE136934T1 (de) 1996-05-15
FI842842A0 (fi) 1984-07-13
DE3486425T2 (de) 1996-10-17
IL108108A0 (en) 1994-04-12
IE64174B1 (en) 1995-07-12
IL91826A (en) 1992-05-25
HUT34543A (en) 1985-03-28
FI842842A7 (fi) 1985-01-16
JP3146161B2 (ja) 2001-03-12
EP0691406A1 (de) 1996-01-10
CZ282867B6 (cs) 1997-11-12
SK278576B6 (en) 1997-10-08
IL101629A0 (en) 1992-12-30
US4831120A (en) 1989-05-16
JPH0799990A (ja) 1995-04-18
JPS6091986A (ja) 1985-05-23
US4871835A (en) 1989-10-03
IL91826A0 (en) 1990-06-10
AU1977788A (en) 1988-12-22
IL72396A0 (en) 1984-11-30
IE841818L (en) 1985-01-15
HU209878B (en) 1994-11-28
JPH09131190A (ja) 1997-05-20
AU577298B2 (en) 1988-09-22
EP0319049A2 (de) 1989-06-07
ZA845345B (en) 1985-03-27
ES534321A0 (es) 1985-12-01
IL112178A0 (en) 1995-03-15
AU615663B2 (en) 1991-10-10
ES544976A0 (es) 1986-01-16
JP2568376B2 (ja) 1997-01-08
DD229427A5 (de) 1985-11-06
BR8403523A (pt) 1985-06-25
EP0319049B1 (de) 1996-04-17
FI90564B (fi) 1993-11-15
NZ208897A (en) 1990-06-26
IL72396A (en) 1992-05-25
IL91828A0 (en) 1990-06-10
IE922469A1 (en) 1985-01-15
NZ227962A (en) 1990-06-26
CZ524684A3 (en) 1997-07-16
US4997916A (en) 1991-03-05
DK347184D0 (da) 1984-07-13
EP0319049A3 (en) 1990-01-03
AU3034584A (en) 1985-01-17
RO91332A (ro) 1987-04-30
JPH0687780B2 (ja) 1994-11-09
DE3486425D1 (de) 1996-05-23
ES8604252A1 (es) 1986-01-16
CA1254527A (en) 1989-05-23
DK347184A (da) 1985-01-16
IL91828A (en) 1992-05-25
FI90564C (fi) 1994-02-25
ATE66959T1 (de) 1991-09-15
RO91332B (ro) 1987-05-01
EP0131843B1 (de) 1991-09-04

Similar Documents

Publication Publication Date Title
EP0131843B1 (de) Expressionsvektoren zur erhöhten Produktion von Polypeptiden, diese Vektoren enthaltende Plasmide, diese Plasmide enthaltenden Wirte, durch die Vektoren hergestellte Produkte und entsprechende Verfahren
KR910002701B1 (ko) 합성 펩티드 및 이를 함유한 제약학적 조성물
EP0518587B1 (de) A-C-B-Proinsulin, Verfahren zu seiner Herstellung und Verwendung, und Zwischenprodukte in der Insulin-Produktion
US5330971A (en) Growth hormone fusion proteins, methods of production, and methods of treatment
JP2857684B2 (ja) ヒトリラキシンの単離のための方法および組成物
CA1340464C (en) Method of producing superoxide dismutase in a bacterial cell
JPH08289792A (ja) ヒトマンガンスーパーオキシドジスムターゼｃＤＮＡ、その細菌中での発現及び酵素活性ヒトマンガンスーパーオキシドジスムターゼの回収方法
US5256546A (en) Bacterial expression of porcine growth hormone
US5637495A (en) Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods
US5527691A (en) Expression vectors containing lambdapl promoter and T1 T2 rRNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and related methods
US5198361A (en) Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods
US5670371A (en) Bacterial expression of superoxide dismutase
US5112744A (en) Plasmids for the production of human Cu-Zn superoxide dismutase, bacterial hosts containing the plasmids and methods for production and recovery of such superoxide dismutase
US5151364A (en) Expression vectors containing lambdapl promoter, T1 T2 RRNA termination sequence, and origin of replication derived from a constitutive high copy number plasmid, and hosts containing the plasmids
US6692941B1 (en) Bovine growth hormone
US5081020A (en) Expression vectors containing λPL promoter, T1 T2 rRNA termination sequence and origin of replication derived from a constitutive high copy number plasmid hosts and related methods
US5147789A (en) Stabilized expression vectors containing lambda pl promoter and the gene for the CI434 repressor, plasmids containing the vectors, hosts containing the plasmids and related methods
JPH01160488A (ja) ポリペプチド類を生産するための新規ベクターおよび発現配列

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20040702

PE Patent expired